In an elderly woman with resistant hypertension (blood pressure >140 mm Hg) despite metoprolol 25 mg daily, losartan 50 mg twice daily, amlodipine 5 mg twice daily, and hydrochlorothiazide 25 mg daily, is adding hydralazine 10 mg twice daily appropriate?

Hydralazine 10 mg BID for Resistant Hypertension in an Elderly Woman

Direct Recommendation

Adding hydralazine 10 mg twice daily is NOT the appropriate next step for this elderly woman with resistant hypertension. Before considering hydralazine as a fourth-line agent, you must first optimize the existing regimen by replacing hydrochlorothiazide with a more potent thiazide-like diuretic (chlorthalidone) and ensuring all current medications are at maximum tolerated doses. 1, 2

---

Current Regimen Assessment

• This patient is on four antihypertensive agents (metoprolol 25 mg, losartan 50 mg BID, amlodipine 5 mg BID, HCTZ 25 mg daily) yet remains uncontrolled with BP >140 mmHg, meeting the definition of resistant hypertension. 2

• Critical problem: The current regimen is suboptimal because:

  • Metoprolol 25 mg daily is a low dose and beta-blockers should NOT be used as routine agents in uncomplicated hypertension in elderly patients unless there are compelling indications (angina, post-MI, heart failure, atrial fibrillation). 1, 3
  • Losartan 50 mg BID totals 100 mg daily, which is the maximum effective dose for hypertension, so this component is optimized. 3
  • Amlodipine 5 mg BID totals 10 mg daily, which is the maximum recommended dose, so this is optimized. 1
  • HCTZ 25 mg is inferior to chlorthalidone for 24-hour BP control and cardiovascular outcomes. 1, 2

---

Recommended Treatment Algorithm

Step 1: Optimize Diuretic Therapy FIRST

Replace HCTZ 25 mg with chlorthalidone 12.5–25 mg once daily. Chlorthalidone provides superior 24-hour BP control, longer duration of action (24–72 hours vs 6–12 hours for HCTZ), and stronger cardiovascular outcome data from the ALLHAT trial. 1, 2

• Monitor serum potassium and creatinine 2–4 weeks after switching diuretics to detect hypokalemia or renal function changes. 1, 2
• In elderly patients, doses of chlorthalidone above 12.5 mg significantly increase the risk of hypokalemia (3-fold higher than lower doses), which eliminates cardiovascular protection and increases sudden death risk. 3

Step 2: Reassess Beta-Blocker Use

Consider discontinuing metoprolol 25 mg unless there is a compelling indication (coronary artery disease, heart failure with reduced ejection fraction, post-MI, or atrial fibrillation requiring rate control). 1, 3

• Beta-blockers are less effective than calcium channel blockers or thiazide diuretics for stroke prevention and cardiovascular event reduction in uncomplicated hypertension in elderly patients. 1, 3, 2
• The 2024 ESC guidelines place beta-blockers only as fourth-line agents after maximized triple therapy (RAS blocker + CCB + diuretic). 2

Step 3: If BP Remains ≥140/90 mmHg After Diuretic Optimization

Add spironolactone 25–50 mg daily as the preferred fourth-line agent for resistant hypertension. Spironolactone provides additional BP reductions of approximately 20–25 mmHg systolic and 10–12 mmHg diastolic when added to triple therapy, addressing occult volume expansion and aldosterone excess that commonly underlie treatment resistance. 1, 2

• Check serum potassium and creatinine 2–4 weeks after initiating spironolactone due to increased hyperkalemia risk when combined with losartan. 1, 2

Step 4: Hydralazine Consideration (Only After Above Steps)

Hydralazine should only be considered as a fifth-line agent after optimizing chlorthalidone, discontinuing or justifying metoprolol, and trialing spironolactone. 1

• If hydralazine is eventually used, confirm it has been titrated to an adequate dose (typically 25–100 mg twice daily) before adding additional agents. 1
• Hydralazine 10 mg BID is a subtherapeutic dose and unlikely to provide meaningful BP reduction. 1

---

Blood Pressure Targets for Elderly Patients

• Primary target: <130/80 mmHg if well-tolerated and the patient is functionally independent. 3, 2
• Minimum acceptable target: <140/90 mmHg for elderly patients, with individualization based on frailty status. 3, 2
• For patients ≥80 years, a target systolic BP of 140–150 mmHg is acceptable, though <140 mmHg is preferred if well-tolerated and the patient is fit. 3
• Reassess BP within 2–4 weeks after any medication change, aiming to achieve target BP within 3 months. 1, 2

---

Monitoring and Safety Considerations

• Orthostatic hypotension: Check BP in both sitting and standing positions at each visit, as elderly patients have increased risk. 3
• Electrolyte monitoring: Elderly patients on chlorthalidone require vigilant potassium monitoring; hypokalemia <3.5 mEq/L eliminates cardiovascular protection. 3
• Renal function: A rise in serum creatinine up to 20% after initiating an ACE inhibitor or ARB is acceptable and does not indicate progressive renal damage. 3

---

Lifestyle Modifications (Adjunctive)

• Sodium restriction to <2 g/day yields a 5–10 mmHg systolic reduction and enhances the efficacy of all antihypertensives, especially diuretics and ARBs. 1, 3
• Weight management (target BMI 20–25 kg/m²) and regular aerobic exercise (≥30 minutes most days) provide cumulative BP reductions of 10–20 mmHg. 1, 2
• Limit alcohol intake to ≤1 drink/day for women. 1

---

Critical Pitfalls to Avoid

• Do NOT add hydralazine before optimizing diuretic therapy (switching to chlorthalidone) and reassessing the need for metoprolol. 1, 2
• Do NOT delay treatment intensification in stage 2 hypertension; prompt action within 2–4 weeks is required to reduce cardiovascular risk. 1, 2
• Do NOT assume treatment failure without first confirming medication adherence (pill counts, pharmacy refill data) and excluding secondary causes of hypertension (primary aldosteronism, renal artery stenosis, obstructive sleep apnea). 1, 2
• Do NOT withhold appropriate treatment intensification solely based on age; individualize BP targets based on frailty and functional status, not chronological age alone. 3, 4